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Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
coronavirus disease 2019 (COVID-19). Sequencing the viral genome as the outbreak progresses is
important, particularly in the identification of emerging isolates with different pathogenic potential
and to identify whether nucleotide changes in the genome will impair clinical diagnostic tools such as
real-time PCR assays. Although single nucleotide polymorphisms and point mutations occur during
the replication of coronaviruses, one of the biggest drivers in genetic change is recombination. This can
manifest itself in insertions and/or deletions in the viral genome. Therefore, sequencing strategies that
underpin molecular epidemiology and inform virus biology in patients should take these factors into
account. A long amplicon/read length-based RT-PCR sequencing approach focused on the Oxford
Nanopore MinION/GridION platforms was developed to identify and sequence the SARS-CoV-2
genome in samples from patients with or suspected of COVID-19. The protocol, termed Rapid
Sequencing Long Amplicons (RSLAs) used random primers to generate cDNA from RNA purified
from a sample from a patient, followed by single or multiplex PCRs to generate longer amplicons of
the viral genome. The base protocol was used to identify SARS-CoV-2 in a variety of clinical samples
and proved sensitive in identifying viral RNA in samples from patients that had been declared
negative using other nucleic acid-based assays (false negative). Sequencing the amplicons revealed
that a number of patients had a proportion of viral genomes with deletions.
Keywords: SARS-CoV-2; next-generation sequencing; amplicon; MinION
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China in 2019 and
has sequence similarity to SARS-CoV and certain bat coronaviruses [1]. After an incubation period
that averages 5 days but may be between two days and two weeks [2], patients with the disease,
termed coronavirus disease 2019 (COVID-19), typically present with fever, myalgia, cough, sore throat,
and difficulty breathing. A range of other symptoms are also possible, in particular gastrointestinal
symptoms. Approximately 80% of infections are mild, but of those that require hospitalisation,
mortality is around 30% [3,4]. SARS-CoV-2 is highly transmissible with a reproductive number (R0) of
around 3 if unmanaged.
SARS-CoV-2 has a positive-sense RNA genome of approximately 30 kb, and viral RNA synthesis
occurs in the cytoplasm of an infected cell. During RNA synthesis, several processes occur
including replication of the genome and transcription of a nested set of subgenomic messenger
RNAs, which encode for the suite of viral proteins, as well as the genome for ORF1AB. During viral
RNA synthesis, errors can occur including point mutation of single nucleic acids and recombination [5].
Recombination events manifest themselves in insertions and/or deletions in the viral genome and
can result in major changes in viral tropism. One of the unusual features of the SARS-CoV-2 genome
sequence, compared to the most closely related coronaviruses, such as SARS-CoV, is the insertion of a
furin cleavage site in the spike glycoprotein (S protein) sequence [6]. The origin of the furin cleavage
site is unknown but may be either viral or cellular in origin. The presence of the furin cleavage site
reduces the dependence on cellular proteases to process the S protein into two functional subunits,
S1 and S2. Thus, recombination can result in the insertion of a non-coronavirus sequence. The furin
cleavage site is potentially unstable [7].
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SARS-CoV-2 has caused a worldwide pandemic and has severe economic and health implications
for all affected countries. Given that mechanisms of both point mutation and recombination operate
in coronaviruses, monitoring for these changes in the SARS-CoV-2 genome is essential not only for
potential contact tracing but also for confidence in vaccine efficacy, which are generally based around
the S protein. Experience from developing vaccines against the coronavirus infectious bronchitis
virus (IBV), which arguably have been the most successful vaccines developed against coronaviruses
so far, has suggested that differences of as little as 5% between the S1 sequences can result in poor
cross-protection against different variants of IBV [8]. Differences in S1 of 2% to 3% (10 to 15 amino
acids) can change serotype, suggesting that a small number of epitopes are immunodominant with
respect to neutralizing antibody [8].
Anecdotal data from diagnostic laboratories (at least based in the UK) early in the outbreak
suggested that nucleic acid-based diagnostics to SARS-CoV-2 and complications around the sampling
processes can lead to unreliable results and false negatives. The advantage of both laboratory [9]
and field-based sequencing [10] approaches in characterising viral infection was illustrated in the
2013–2016 West African Ebola virus outbreak, and allowed the origin of clusters of infection to
be rapidly identified [11]. Therefore, the accurate identification and sequencing of SARS-CoV-2 in
samples from patients provide multiple information from reducing false negatives, contact tracing,
to assessing the suitability of diagnostic assays (especially nucleic acid-based) and investigating
whether vaccines are likely to be or remain efficacious in the background of nucleotide substitution
and recombination during virus replication. The International Severe Acute Respiratory and emerging
Infection Consortium (ISARIC) 4C UK study provided a large and detailed collection of sequentially
collected virological samples from well-characterised hospitalised patients; here we assess the utility of
the Rapid Sequencing Long Amplicon (RSLA) protocol in monitoring viral RNA from early participants.
2. Materials and Methods
2.1. Ethics and Clinical Information
Patients (n = 24) were recruited under the International Severe Acute Respiratory and Emerging
Infection Consortium (ISARIC) Clinical Characterisation Protocol (CCP) (https://isaric.net/ccp) by
giving informed consent. ISARIC CCP was reviewed and approved by the national research ethics
service, Oxford (13/SC/0149). Samples from clinical specimens were processed at CL3 in the Outbreak
Response Laboratory at the University of Liverpool, Liverpool, UK.
2.2. RNA Extraction and Preparation
Nasopharyngeal swabs were collected into viral transport medium from patients with COVID-19.
RNA was isolated using either a QIAamp Viral RNA Mini Kit (Qiagen, Mancheste, UK) by spin-column
procedure or Trizol LS (Invitrogen, UK), according to the manufacturer’s instructions. Total RNA
was purified from SARS-CoV-2 infected Vero cells following AVL inactivation using the Qiagen RNA
Mini Kit. Infection of Vero cells was conducted at Public Health England, Porton Down at CL3.
RNA samples were treated with Turbo DNase (Invitrogen).
2.3. Primer Design
Alignments generated from the NCBI reference sequence for SARS-CoV-2 NCBI (NC_045512.2)
and published sequences on GISAID were used to identify conserved regions for primer design.
Primers (Table 1) were chosen that sequentially amplified roughly 1000 bp with an ~200 bp
overlapping region.
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Table 1. Primer pairs by sequence order.
Primer Name Sequence 5′–3′
Location Size
(bp)
Multiplex Pool
Start End
SARS-CoV-2_1_F GTGTGACCGAAAGGTAAGATGG 248 269
956 1
SARS-CoV-2_1_R TTGCATTCATTTGGTGACGC 1203 1184
SARS-CoV-2_2_F GGTGTATACTGCTGCCGTGA 944 963
1213 2
SARS-CoV-2_2_R GCCAATCAAGGACGGGTTTG 2156 2137
SARS-CoV-2_3_F CCGCACTCTTGAAACTGCTC 1912 1931
1254 3
SARS-CoV-2_3_R GCAGAAGTGGCACCAAATTC 3165 3146
SARS-CoV-2_4_F ACACCACTGGGCATTGATTTAG 2936 2957
1264 4
SARS-CoV-2_4_R TTTCAGTAGTGCCACCAGCC 4199 4180
SARS-CoV-2_5_F CTTCATCCAGATTCTGCCAC 4052 4071
1296 5
SARS-CoV-2_5_R AGCAGGTGGATTAAACTTCAACTC 5347 5324
SARS-CoV-2_6_F CAACATTAACCTCCACACGC 4990 5009
1189 6
SARS-CoV-2_6_R ATCAATAGCCACCACATCACC 6178 6158
SARS-CoV-2_7_F AGAAACCTGCTTCAAGAGAGC 6108 6128
1373 1
SARS-CoV-2_7_R ATTACAACCGTCTACAACATGCAC 7480 7457
SARS-CoV-2_8_F GTCACTATTGCAACCTACTGTAC 7091 7113
1093 2
SARS-CoV-2_8_R CTTGCCGAGCTGCTGAAATA 8183 8164
SARS-CoV-2_9_F AATCAGCGTCTGTTTACTACAGTC 7929 7952
1192 3
SARS-CoV-2_9_R GTGTCAGGGCGTAAACTTTC 9120 9101
SARS-CoV-2_10_F TTGTCGTGCCTGGTTTGC 8856 8873
1303 4
SARS-CoV-2_10_R ACGTCATCAAGCCAAAGACC 10158 10139
SARS-CoV-2_11_F AGTGGAGCAATGGATACAAC 9917 9936
1239 5
SARS-CoV-2_11_R AGCTACAGTGGCAAGAGAAG 11209 11190
SARS-CoV-2_12_F AGGGTACACACCACTGGTTG 10995 11014
1185 6
SARS-CoV-2_12_R CACCATTAGCAACAGCCTGC 12179 12160
SARS-CoV-2_13_F GTGAAGAAATGCTGGACAACAG 12057 12078
1180 1
SARS-CoV-2_13_R GCACCACCAAAGGATTCTTG 13236 13217
SARS-CoV-2_14_F TAGTTTAGCTGCCACAGTACG 12997 13017
1200 2
SARS-CoV-2_14_R AGTTAAAGCCCTGGTCAAGG 14196 14177
SARS-CoV-2_15_F ATACGCCAACTTAGGTGAACG 13962 13982
1284 3
SARS-CoV-2_15_R AACATGTTGTGCCAACCACC 15245 15226
SARS-CoV-2_16_F TGAGTTATGAGGATCAAGATGCAC 14996 15019
1243 4
SARS-CoV-2_16_R GCCTGTAAGACTGTATGCGG 16238 16219
SARS-CoV-2_17_F CCCAGATCCATCAAGAATCCTAG 15933 15955
1214 5
SARS-CoV-2_17_R TGCGAGCAGAAGGGTAGTAG 17146 17127
SARS-CoV-2_18_F AAGGTGACTATGGTGATGCTG 16841 16861
1336 6
SARS-CoV-2_18_R GGTATGCCAGGTATGTCAACAC 18176 18155
SARS-CoV-2_19_F ACTCAAACCACTGAAACAGCTC 17875 17896
1239 1
SARS-CoV-2_19_R GTCACTACAAGGCTGTGCATC 19113 19093
SARS-CoV-2_20_F AGCTAGTTGTGATGCAATCATGAC 18846 18869
1235 2
SARS-CoV-2_20_R CTTGTTTGGGACCTACAGATGG 20098 20077
SARS-CoV-2_21_F TTTGGGTGTGGACATTGCTG 19842 19861
1323 3
SARS-CoV-2_21_R ATAGCCACGGAACCTCCAAG 21164 21145
SARS-CoV-2_22_F TAAGACAGTGGTTGCCTACG 20912 20931
1125 4
SARS-CoV-2_22_R TCTGAACTCACTTTCCATCCAAC 22036 22014
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Table 1. Cont.
Primer Name Sequence 5′–3′
Location Size
(bp)
Multiplex Pool
Start End
SARS-CoV-2_23_F TTCGAAGACCCAGTCCCTAC 21895 21914
1405 5
SARS-CoV-2_23_R TGGATCACGGACAGCATCAG 23299 23280
SARS-CoV-2_24_F TTGAACTTCTACATGCACCAGC 23106 23127
1111 6
SARS-CoV-2_24_R CCAGAAGTGATTGTACCCGC 24216 24197
SARS-CoV-2_25_F TTGCTGCTAGAGACCTCATTTG 24093 24114
1190 1
SARS-CoV-2_25_R GCAACTGGTCATACAGCAAAG 25282 25262
SARS-CoV-2_26_F GGTGACATCTCTGGCATTAATGC 25061 25083
1163 2
SARS-CoV-2_26_R TGCTTACAAAGGCACGCTAG 26223 26204
SARS-CoV-2_27_F ACCAGCTGTACTCAACTCAATTG 26027 26049
1137 3
SARS-CoV-2_27_R CTGCTACTGGAATGGTCTGTG 27163 27143
SARS-CoV-2_28_F TGACCAGACCGCTTCTAGAAAG 26908 26929
1180 4
SARS-CoV-2_28_R GCCTCATCCACGCACAATTC 28087 28068
SARS-CoV-2_29_F TGTCACGCCTAAACGAACATG 27876 27896
1147 5
SARS-CoV-2_29_R GATTTCTTAGTGACAGTTTGGCC 29022 29000
SARS-CoV-2_30_F CGAATTCGTGGTGGTGACG 28550 28568
1173 6
SARS-CoV-2_30_R GGTGGCTCTTTCAAGTCCTC 29722 29703
2.4. RT and PCR
SuperScript IV (Invitrogen) was used to generate single-strand cDNA using random primer mix
(NEB, Hitchin, UK). The primer sets were used to generate 30 amplicons from the cDNA. Subsequently,
primers were pooled to generate six sets each containing five primer pairs. Reactions were performed
using 2 × Q5-High Fidelity master mix (NEB) with 0.5 µM of each primer for the individual reactions
and 0.1µM of each primer for the pooled primers. The reaction conditions were as follows: denaturation
at 98 ◦C for 30 sec followed by 35 to 40 cycles of 10 sec denaturation at 98 ◦C, 30 sec annealing at 66 ◦C
and then 50 sec of extension at 72 ◦C. A final extension step was done for 2 min at 72 ◦C.
2.5. Library Preparation for MinION Sequencing
Following amplification, PCR products were purified at a 1:1 ratio with AMPure XP beads
(Beckman Coulter, High Wycombe, UK). The library was prepared as per the sequencing by ligation
protocol with native barcodes for multiplexing (Oxford Nanopore, Oxford, UK).
2.6. Informatics Analysis
For assembly of the SARS-CoV-2 genomes, Minimap2 (v. 2.17-r941) was used to align fastq
sequences to the coronavirus 2 isolate Wuhan-Hu-1 reference genome (NC_045512.2) using the -ax
map-ont parameters. Samtools (v.1.10) was used to sort and index alignment files, and Picard (v.2.23.4)
was used to mark duplicates. A custom script written in perl (v.5.26.2) was used to determine viral
genome coverage, the viral consensus sequence and the presence of indels. Viral genome coverage
was visualised in RStudio (v. 4.0.2). For the identification of deletions within the SARS-CoV-2 genome,
ONT RSLA library reads were aligned to the coronavirus 2 isolate Wuhan-Hu-1 reference genome using
Minimap2, as part of the Nextflow ARTIC analysis pipeline (https://github.com/connor-lab/ncov2019-
artic-nf). Raw aligned BAM files were used as input to SVIM, to detect putative deletions. Resulting
candidate deletions were filtered to accept any with at least 5 supporting reads and intersected with
reference gene annotations to determine which genes intersected with the deletions.
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3. Results
3.1. Primer and Amplicon Design
To sequence SARS-CoV-2 with a view to identify both nucleotide polymorphisms and
recombination events on the viral genome, a longer read length amplicon-based system was developed.
A series of primers were designed (Table 1), allowing overlapping sections of the SARS-CoV-2 genome
to be amplified sequentially in 1000 base-paired fragments, with an approximately 200 base pair
overlap to facilitate sequence assembly from the amplicon data (Figure 1A). The primers were selected
on the basis of conserved regions in the SARS-CoV-2 genome based upon an initial deposition of
17 genomes available on GISAID.Viruses 2020, 12, x   6 of 17 
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Figure 1. (A) Schematic diagram of the severe acute res iratory syndrome coronavirus 2 (SARS-CoV-2)
genome showing the position of major open reading frames and the position of the amplicons along the
genome. (B) Agarose gel electrophoresis analysis of the amplicon products resulting from RT-PCR using
the designated forward and reverse primers to amplify the SARS-CoV-2 genome from RNA purified
from Vero cells infected with the virus. (C) The amplicon products were purified and sequenced on a
single flow cell using an Oxford Na opore MinION. Shown are the number of reads that map (y-axis)
to each amplicon across the SARS-CoV-2 genome from 5′ to 3′ (x-axis).
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3.2. Validation of Amplicon Generation and Oxford Nanopore Sequencing Using RNA from Cells Infected with
SARS-CoV-2
Purified RNA from SARS-CoV-2 (MT007544.1 GenBank)-infected Vero cells was used to confirm
that the primers could generate amplicons. This RNA was used as a template for cDNA synthesis
followed by PCR using the conserved primers. This generated 30 separate amplicons covering the
SARS-CoV-2 genome, and the synthesis and expected size of these amplicons were confirmed using
agarose gel electrophoresis (Figure 1B). These amplicons were sequenced on an Oxford Nanopore
(UK) flow cell using MinION and reads were mapped to the SARS-CoV-2 genome confirming that the
amplicons represented viral sequence (Figure 1C). This approach was termed Rapid Sequencing Long
Amplicons (RSLAs).
3.3. Initial Evaluation of the Amplicon Approach to Detect SARS-CoV-2 on RNA Purified from Nasopharyngeal
Swabs Collected from Patients with COVID-19 Correctly Identified a Positive but also a False Negative Sample
The ability of the amplicon-based approach to detect SARS-CoV-2 was initially evaluated on
nasopharyngeal swabs collected from patients with COVID-19. The first patient (REMRQ0001) was
admitted to the Royal Liverpool University Hospital on 23 February 2020. The patient was a member of
staff from the Diamond Princes cruise ship that had an outbreak of SARS-CoV-2 leading to passengers
developing COVID-19 [12,13]. The patient was asymptomatic but was screened for SARS-CoV-2 on
20 February 2020, left the ship on 21 February and was repatriated from Japan on 22 February 2020.
During the flight, a positive result for SARS-CoV-2 using a nucleic acid-based system was received.
A repeat nasopharyngeal swab was taken on admission and again tested positive with a viral load of
Ct = 31.3. Two repeat swabs were collected on 24 February, one was positive (Ct = 32.7) and the second
was negative. On 25 February, a fourth diagnostic swab was again negative, but a separately collected
swab yielded PCR products from RNA isolated to evaluate the amplicon system. Here, 30 separate
amplicons were synthesized and then visualised by agarose gel electrophoresis (Figure 2A). The data
indicated that all amplicons (F1&R1 to F30&R30) could be identified and spanned the SARS-CoV-2
genome. These amplicons were sequenced on an Oxford Nanopore flow cell using MinION and
sequence reads were mapped to the SARS-CoV-2 genome (Figure 2B), confirming that the amplicons
represented viral sequence.
A final nasopharyngeal swab was taken from patient REMRQ0001 on 27 February. This latter
swab was not used for a diagnostic assay but was used to evaluate the sensitivity of the amplicon-based
system using RNA isolated from the sample. In this case, several amplicon products were identified,
though fewer than on the previous sample (note that the brightness on the gel image was adjusted
post-exposure to show these products more clearly) (Figure 2C). The products most clearly visible
included amplicons from the polymerase (orf1ab) region (F1&R1, F3&R3, F7&R7, F12&R12, F15&R15,
F16&R16, F20&R20) and the membrane (M) region (F26&R26). Other amplicon products were less
visible including F28&R28, spanning the orf8/nucleoprotein gene sequence. Therefore, the data
suggested that the viral genome or viral sequence was present in a patient that had been evaluated
as negative.
The second patient (REMRQ0002) had onset of symptoms of COVID-19 on 22 February 2020
and was admitted to the Royal Liverpool University Hospital on 27 February 2020 after a diagnostic
nasopharyngeal swab taken on 25 February tested positive for SARS-CoV-2. A repeat swab taken on
the day of admission against tested positive for SARS-CoV-2. A further swab was taken for research the
same day, and RNA isolated from this swab was used to evaluate the amplicon system. The amplicons
were visualised by agarose gel electrophoresis (Figure 3A,B; same gel as shown in 3A but with the
brightness enhanced post-image capture). These amplicons were sequenced on an Oxford Nanopore
flow cell using MinION and sequence reads were mapped to the SARS-CoV-2 genome (Figure 3C),
confirming that the amplicons represented viral sequence. There were some regions of the genome
that had lower sequence read depth.
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Figure 2. (A) Agarose gel electrophoresis analysis of amplicons generated by RT-PCR from RNA
isolated from a nasopharyngeal swab taken from patient REMRQ0001, who had coronavirus disease
2019 (COVID-19), and diagnosed positive for SARS-CoV-2 by a laboratory-based test. Primer pairs are
indicated above each amplicon. (B) The amplicon products were purified and sequenced on a single
flow cell using an Oxford Nanopore MinION. Shown are the number of reads that map (y-axis) to
each amplicon across the SARS-CoV-2 genome from 5′ to 3′ (x-axis). ( ) Agarose gel electrophoresis
analysis of amplicons generated by RT-PCR from RNA isolated from a nasopharyngeal swab taken
from patient REMRQ0001, who had COVID-19, and subsequently found negative for SARS-CoV-2 by a
laboratory-based test. Note that the brightness of the image has been adjusted post-image capture to
more clearly show amplicon products.
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Figure 3. (A,B) Agarose gel electrophoresis analysis of amplicons generated by RT-PCR from RNA
isolated from a nasopharyngeal swab taken from patient REMRQ0002, who had COVID-19, and
diagnosed positive for SARS-CoV-2 by a laboratory-based test. Primer pairs are indicated above each
amplicon. Note that the image in (B) is the same image as (A) but the brightness has been enhanced
post-image capture in order to more clearly show amplicon products. (C) The amplicon products
were purified and sequenced on a single flow cell using an Oxford Nanopore MinION. Shown are
the number of reads that map (y-axis) to each amplicon across the SARS-CoV-2 genome from 5′ to 3′
(x-axis).
3.4. Development of a Multiplex Method to Generate Amplicons
In order to increase capacity and reduce complexity (the need to conduct individual PCRs for each
amplicon primer set), primer sets were pooled into six groups (Table 1). These were arranged so that
adjacent regions were not in the same pool and that there was coverage across the genome in each pool.
This way, if a reaction failed, there would still be genome coverage in each amplicon group. The ability
of this multiplex method to identify SARS-CoV-2 RNA in clinical material was evaluated by isolating
RNA from nasopharyngeal swabs taken from patients. Total RNA from SARS-CoV-2 infected cells was
also used as a positive control, and negative controls were also included. The six groups of primer sets
were used to generate a mixture of amplicons in each pool for each patient and the positive control.
These amplicons were visualised by agarose gel electrophoresis (exemplar data shown in Figure 4).
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3.5. Identification of Deletions in SARS-CoV-2 from Patients with COVID-19
Recombination is a major mechanism of genetic change in coronaviruses, and this will manifest
in insertions and deletions being present in the SARS-CoV-2 genome [7]. For coronaviruses in
general, this process is well characterised in cell culture and has been demonstrated in vivo for
both animal coronaviruses [5] and also in humans for Middle East respiratory syndrome coronavirus
(MERS-CoV) [14,15]. To assess whether and where these were occurring during SARS-CoV-2 replication
in patients, RNA was extracted from nasopharyngeal swabs taken from 24 patients and amplicons
generated using the RSLA multiplex approach and sequenced on Oxford Nanopore flow cells using
either MinION and/or GridION. Sequence reads were mapped to the SARS-CoV-2 genome and putative
deletions identified (Table 2). Interestingly, several patients had deletions, at the minor variant level,
in the SARS-CoV-2 genome scored with high confidence, mainly in orf3a and orf7a, which are associated
with interferon antagonism and would result in potential defective genomes being present.
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Table 2. Analysis of deletions in the SARS-CoV-2 genome in patients with COVID-19. The columns from left to right are as follows: sample barcode, deletion start
position (bp), deletion end position (bp), number of reads supporting this deletion, quality score (similar to number of reads supporting, but also takes into account
read mapping quality scores with a score greater than 10 having higher confidence), standard deviation (SD) of deletion span (bp) from supporting reads, SD of
deletion position (bp) from supporting reads. If the deletion interrupts a gene, these are the coordinates of the gene, the gene name, and the bp overlap with the
deletion. In cases where the deletion overlaps >1 gene, the information of the second gene is provided.
Deletion Information Affected Gene Information
Patient
Number
Start
(bp)
End
(bp)
Supporting
Reads
Quality
Score
SD
Span SD Pos
Gene
Start
Gene
End
Gene
Name
Overlap
(bp)
Gene2
Start
Gene2
End
Gene2
Name
Overlap2
(bp)
22 19325 19380 9 10 4.42 58.42 266 21555 Orf1ab 55 − − − −
22 20294 20429 8 10 0 0 266 21555 Orf1ab 135 − − − −
22 25417 25796 10 12 0.79 0.86 25393 26220 Orf3a 379 − − − −
22 27578 27624 16 19 2.49 2.45 27394 27759 Orf7a 46 − − − −
22 28756 28884 7 8 2.27 3.4 28274 29533 N 128 − − − −
23 2143 2198 5 5 4.36 73.69 266 21555 Orf1ab 55 − − − −
23 2375 2421 8 8 5.54 82.85 266 21555 Orf1ab 46 − − − −
23 2589 2642 6 6 3.2 41.78 266 21555 Orf1ab 53 − − − −
23 2654 2741 5 5 8.73 51.88 266 21555 Orf1ab 87 − − − −
23 2859 2904 9 10 2.42 88.48 266 21555 Orf1ab 45 − − − −
25 20274 20383 7 8 6.2 7.5 266 21555 Orf1ab 109 − − − −
25 20279 20340 10 12 3.83 2.57 266 21555 Orf1ab 61 − − − −
25 27594 27640 10 11 2.37 31.77 27394 27759 Orf7a 46 − − − −
26 27386 27699 91 99 0.86 1.66 27394 27759 Orf7a 305 27202 27387 ORF6 1
26 20274 20338 9 11 1.5 1.02 266 21555 Orf1ab 64 − − − −
27 27020 27073 11 13 0.6 0.3 26523 27191 M 53 − − − −
27 27522 27761 24 29 1.09 2.04 27394 27759 Orf7a 237 − − − −
27 27689 27763 23 27 3.58 29.9 27394 27759 Orf7a 70
28 2025 2088 5 5 7.16 80.94 266 21555 Orf1ab 63
28 25508 25568 6 6 8.31 61.45 25393 26220 Orf3a 60
28 27884 27934 6 6 7.19 27.43 27894 28259 Orf8 40
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Table 2. Cont.
Deletion Information Affected Gene Information
Patient
Number
Start
(bp)
End
(bp)
Supporting
Reads
Quality
Score
SD
Span SD Pos
Gene
Start
Gene
End
Gene
Name
Overlap
(bp)
Gene2
Start
Gene2
End
Gene2
Name
Overlap2
(bp)
29 27546 27650 7 8 14.61 64.8 27394 27759 Orf7a 104
29 28454 28731 6 7 26.89 58.79 28274 29533 N 277
30 25398 25776 12 14 1.56 69.87 25393 26220 Orf3a 378
30 27555 27625 31 38 1.94 5.71 27394 27759 Orf7a 70
30 8676 8723 11 12 1.79 38.61 266 21555 Orf1ab 47
31 28444 28775 62 77 1.29 1.31 28274 29533 N 331
32 25480 25551 97 99 1.62 2.04 25393 26220 Orf3a 71
36 20274 20339 11 13 1.43 0.87 266 21555 Orf1ab 65
37 25429 25641 11 13 17 7.89 25393 26220 Orf3a 212
37 25432 25808 10 12 5.24 44.62 25393 26220 Orf3a 376
37 28444 28776 8 9 0.71 0.65 28274 29533 N 332
43 27426 27559 5 5 19.77 50.25 27394 27759 Orf7a 133
43 27690 27732 6 6 2.25 49.85 27394 27759 Orf7a 42
43 28011 28062 13 14 5.36 77.82 27894 28259 Orf8 51
43 28196 28238 5 5 2 96.73 27894 28259 Orf8 42
43 28481 28536 5 5 3 64.73 28274 29533 N 55
28601 28718 5 5 4.82 43.76 28274 29533 N 117
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4. Discussion
This work demonstrates that both amplicon-based detection and subsequent sequencing are
feasible for identifying the SARS-CoV-2 genome or nucleic acid in samples from patients with COVID-19.
The rationale is based on amplifying and sequencing longer fragments than comparative techniques,
and our approach was named Rapid Sequencing Long Amplicons (RSLAs) to reflect this and its
origins based on identifying MERS-CoV from viral subgenomic messenger RNAs present in clinical
samples in Saudi Arabia. The amplicon system was evaluated first on RNA purified from cells
infected with SARS-CoV-2 as a positive control and then on RNA purified from nasopharyngeal swabs
from patients with COVID-19. We would note that this system best lends itself to identifying and
sequencing SARS-CoV-2 from RNA that is of good quality. In general, the Ct value of these diagnostic
leftover samples was not known. Different platforms are used in different settings and diagnostic
laboratories in the UK, and there is no common uniformity. Interestingly, the RSLA system could
identify nucleic acid corresponding to parts of the SARS-CoV-2 genome in a sample from a patient that
had tested SARS-CoV-2 negative by an alternative diagnostic nucleic acid-based test performed on
a separate sample. Provided that the primer binding sites remain conserved in the pathogen being
tested, RT-qPCR is generally more sensitive for diagnostic purposes. In this case, diagnostic reagents
for RT-qPCR can be reassessed based upon using sequencing as sentinel for these events. We would
note that, based upon our comparison, multiple sites should be targeted within the genome to increase
diagnostic sensitivity. Not all regions of the viral genome had equal sequence coverage, and this
may be reflective of differential RNA stability in a clinical sample and the gradient of subgenomic
messenger RNAs. Nevertheless, there was sufficient coverage to build consensus genomes.
The non-multiplexed RSLA approach has been compared to other viral genome sequencing
protocols such as ARTIC and viral bait capture, using the Illumina MiSeq platform, further demonstrating
the feasibility and flexibility of this method. Although RSLA generates less depth in comparison to
other methods, the breadth of coverage tends to be more even [16]. RNA quality and viral load (Ct
values) can influence sequence read depth and obtaining full genome coverage regardless of method.
Previous studies on sequencing viral genomes and investigating depth of coverage and accuracy of base
calling have shown that MinION sequencing is comparable to short-read sequencing platforms such as
Illumina [17,18]. Long-read sequencing data has advantages in detecting insertions and deletions and
allows linkage of potentially different sequence variations. These can be missed depending on the type
of bioinformatic analysis in short-read data. Much needed information can be gained from sequencing
of viral genomes in terms of viral adaptation [9], thus informing molecular epidemiological studies
during outbreaks [18]. Current diagnostics may not remain fit for purpose due to recombination in
coronaviruses (e.g., [5,19]). Interestingly, analysis of deletions that occurred in the SARS-CoV-2 genome
in infected patients from this study identified several that mapped to genes encoding proteins involved
in interferon and host antagonism. Deletions with high confidence scores were particularly situated in
Orf3a but particularly in Orf7a. These genes are conserved with SARS-CoV [20]. ORF3A in SARS-CoV
has been shown to activate the NLRP3 inflammasome [21], induce NF-κB activation and chemokine
production [22] and may act as a viroporin. Data from SARS-CoV suggested that ORF7A acts as an
RNA silencing suppressor (RSS) and therefore is a suppressor of siRNA activity in mammalian cells [23].
The presence of deletion variants of the genome may also act as defective interfering genomes within
patients. Such deletion variants may account for the transient emergence of isolates of SARS-CoV-2 that
are associated with the milder disease in patients [24].
While most analysis of genome variation in viruses with RNA genomes is focused on nucleotide
substitution, it is recombination in coronaviruses that is one of the big drivers of adaptation and change.
A novel genotype of human coronavirus OC43 has been shown to emerge through recombination [25].
Indeed, recombination in coronaviruses can occur between highly divergent coronaviruses of the same
strain [26] and even between coronaviruses that infect different species [27], as has been proposed for
the origin of these severe coronaviruses in humans. Therefore, we would caution that any surveillance
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and sequencing pipeline is able to identify recombination and monitor for recombination between
SARS-CoV-2 and other coronaviruses—particularly human ones.
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